A new scientific paradigm may be needed to finally develop an HIV vaccine

Frontiers in Immunology

Volumn 6, Issue MAR, 2015, Pages

  Esparza, José ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

HIV 1 vaccines; Innovation; Non neutralizing antibodies; Paradigm shift; Vaccine efficacy trials

Indexed keywords

HEMAGGLUTININ; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN;

ANTIBODY RESPONSE; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); CYTOTOXIC T LYMPHOCYTE; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; VIRUS INFECTION;

EID: 84926658121     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00124     Document Type: Review

References (88)

1. Kuhn TS. The Structure of Scientific Revolutions. Chicago: University of Chicago Press (1962).
2. Richmond PA. The germ theory of disease. Henry E Sigerist Suppl Bull Hist Med (1980) 4:84-98.
3. Smith KA. Louis pasteur, the father of immunology? Front Immunol (2012) 3:68. doi: 10.3389/fimmu.2012.00068.
4. Gallo RC. The discovery of the first human retroviruses: HTLV-1 and HTLV-2. Retrovirology (2005) 2:17. doi:10.1186/1742-4690-2-S1-S17.
5. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphomas. Proc Nat Acad Sci U S A (1980) 77:7415-9. doi:10.1073/pnas.77.12.7415.
6. DeVita VT. A perspective on the war on cancer. Cancer J (2002) 5:352-6. doi:10.1097/00130404-200209000-00002.
7. Judson HC. The Eight Day of Creation-the Makers of the Revolution in Biology. New York: Simon and Schuster (1979).
8. Rott R. The post-Loeffler-Frosch era: contribution of German virologists. In: Calisher CH, Horzinek MC, editors. 100 Years of Virology: The Birth and Growth of a Discipline. Vienna: Springer (1999). p. 43-61.
9. Schäfer W. Structure of some animal viruses and significance of their components. Bacteriol Rev (1963) 27:1-17.
10. Ihle JN, Collins JJ, Lee JC, Fischinger PJ, Moenning V, Schäfer W, et al. Characterization of the immune response to the major glycoprotein (gp 71) of Friend leukemia virus. I. Response in BALB/c mice. Virology (1976) 75:74-87. doi:10.1016/0042-6822(76)90008-8.
11. Bolognesi DP, Fischinger PJ. Prospects for treatment of human retrovirus-associated diseases. Cancer Res (1985) 45:470s-5s.
12. Fischinger PJ, Gallo RC, Bolognesi DP. Toward a vaccine against AIDS: rationale and current progress. Mt Sinai J Med (1986) 53:639-47.
13. Robey WG, Arthur LO, Matthews TJ, Langlois A, Copeland TD, Lerche NW, et al. Prospects for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. Proc Natl Acad Sci U S A (1986) 83:7023-7. doi:10.1073/pnas.83.18.7023.
14. Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature (1982) 298:347-50. doi:10.1038/298347a0.
15. McAleer WC, Bynak EB, Maigetter RZ, Wampler DE, Miler WJ, Hileman MR. Human hepatitis from recombinant yeast. Nature (1984) 307:178-80. doi:10.1038/307178a0.
16. Fischinger PJ, Robey WG, Koprowsky H, Gallo RC, Bolognesi D. Current status and strategies for vaccines against diseases induced by human T-cell lymphotropic retroviruses (HTLV-I,-II,-III). Cancer Res (1985) 45(9 Suppl):4694s-9s.
17. Esparza J. A brief history of the global effort to develop a preventive HIV vaccine. Vaccine (2013) 31:3502-18. doi:10.1016/j.vaccine.2013.05.018.
18. Esparza J, Russell N, McCutchan F. The long road to an HIV vaccine. In: Kleinman DL, Delbourne J, Cloud-Hansen KA, Handelsman J, editors. Controversies in Science and Technology. (Vol. 3), New York, NY: Mary Ann Liebert Inc Publishers (2010). p. 44-76.
19. Lewis GK, DeVico AL, Gallo RC. Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development. Proc Natl Acad Sci U S A (2014) 111:15614-21. doi:10.1073/pnas.1413550111.
20. Carnathan DG, Wetzel KS, Yu J, Lee ST, Johnson BA, Paiardini M, et al. Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques. Proc Natl Acad Sci U S A (2015) 112:518-23. doi:10.1073/pnas.1407466112.
21. Fouts TR, Bagley K, Prado IJ, Bobb KL, Schwartz JA, Xu R, et al. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proc Natl Acad Sci U S A (2015) 112(9):E992-9. doi:10.1073/pnas.1423669112.
22. Esparza J. What has 30 years of HIV vaccine research taught us? Vaccines (2013) 1:513-26. doi:10.3390/vaccines1040513.
23. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 191:654-65. doi:10.1086/428404.
24. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 194:1661-71. doi:10.1086/508748.
25. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 372:1881-93. doi:10.1016/S0140-6736(08)61591-3.
26. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 361:2209-20. doi:10.1056/NEJMoa0908492.
27. Bolognesi DP, Matthews TJ. HIV vaccines viral envelope fails to deliver? Nature (1999) 391:638-9. doi:10.1038/35504.
28. Shaw GM, Hunter E. HIV transmission. Cold Spring Harb Perspect Med (2012) 2(11):1-23. doi:10.1101/cshperspect.a006965.
29. Nkolola JP, Bricault CA, Cheung A, Shields J, Perry J, Kovacs JM, et al. Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer. J Virol (2014) 88:9538-52. doi:10.1128/JVI.01739-14.
30. Yasmeen A, Ringe R, Derking R, Cupo A, Julien JP, Burton DR, et al. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology (2014) 11:41. doi:10.1186/1742-4690-11-41.
31. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci U S A (1989) 86:6768-72. doi:10.1073/pnas.86.17.6768.
32. Li D, Forrest BD, Li Z, Xue P, Hanson CV, Duan S, et al. International clinical trials of HIV vaccines: II. Phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China. Asian Pac J Allergy Immunol (1997) 15:105-13.
33. Steimer KS, Scandella CJ, Skiles PV, Haigwood NL. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science (1991) 254:105-8. doi:10.1126/science.1718036.
34. Kwong PD, Mascola JR, Nabel GJ. Rational design of vaccines to elicit broadly neutralizing antibodies to HV-1. Cold Spring Harb Perspect Med (2011) 1(1):a007278. doi:10.1101/cshperspect.a007278.
35. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, et al. A blueprint for HIV vaccine discovery. Cell Host Microbe (2012) 12:396-407. doi:10.1016/j.chom.2012.09.008.
36. McLellan JS, Correia BE, Chen M, Yang Y, Graham BS, Schief WR, et al. Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol (2011) 409:853-66. doi:10.1016/j.jmb.2011.04.044.
37. Van Regenmortel MH. Basic research in HIV vaccinology is hampered by reductionist thinking. Front Immunol (2012) 3:194. doi:10.3389/fimmu.2012.00194.
38. Van Regenmortel MH. An outdated notion of antibody specificity is one of the major detrimental assumptions of the structure-based reverse vaccinology paradigm, which prevented it from helping to develop an effective HIV-1 vaccine. Front Immunol (2014) 5:593. doi:10.3389/fimmu.2014.00593.
39. Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev (2013) 254:225-44. doi:10.1111/imr.12075.
40. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol (2012) 30:423-33. doi:10.1038/nbt.2197.
41. Ahlers JD. All eyes on the next generation of HIV vaccines: strategies for inducing a broadly neutralizing antibody response. Discov Med (2014) 17:187-99.
42. Prabakaran P, Chen W, Dimitrov DS. The antibody germline/maturation hypothesis, elicitation of broadly neutralizing antibodies against HIV-1 and cord blood IgM repertoires. Front Immunol (2014) 5:398. doi:10.3389/fimmu.2014.00398.
43. Stephenson KE, Barouch DH. A global approach to HIV-1 vaccine development. Immunol Rev (2013) 254:295-304. doi:10.1111/imr.12073.
44. Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 155:531-9. doi:10.1016/j.cell.2013.09.061.
45. Barouch DH, Picker LJ. Novel vaccine vectors for HIV-1. Nat Rev Microbiol (2014) 12:765-71. doi:10.1038/nrmicro3360.
46. Teigler JE, Phogat S, Franchini G, Hirsch VM, Michael NL, Barouch DH. The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys. J Virol (2014) 88:1809-14. doi:10.1128/JVI.02386-13.
47. Perdiguero B, Gómez CE, Cepeda V, Sánchez-Sampedro L, García-Arriaza J, Mejías-Pérez E, et al. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as VLPs. J Virol (2014) 89(2):970-88. doi:10.1128/JVI.02469-14.
48. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 473:523-7. doi:10.1038/nature10003.
49. Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz BJ, Scholz I, et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science (2013) 340:1237874. doi:10.1126/science.1237874.
50. Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine development. Annu Rev Med (2012) 63:95-111. doi:10.1146/annurev-med-042010-085643.
51. Picker LJ. Are effector memory T cells the key to an effective HIV/AIDS vaccine? EMBO Rep (2014) 15:820-1. doi:10.15252/embr.201439052.
52. Fauci AS, Folkers GK, Marston HD. Ending the global HIV/AIDS pandemic: the critical role of an HIV vaccine. Clin Infect Dis (2014) 59(Suppl 2):S80-4. doi:10.1093/cid/ciu420.
53. Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 303:316. doi:10.1126/science.1094620.
54. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 366:1275-8. doi:10.1056/NEJMoa1113425.
55. Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 6:228ra39. doi:10.1126/scitranslmed.3007730.
56. Veillette M, Désormeaux A, Medjahed H, Gharsallah NE, Coutu M, Baalwa J, et al. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J Virol (2014) 88:2633-44. doi:10.1128/JVI.03230-13.
57. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 86:11521-32. doi:10.1128/JVI.01023-12.
58. DeVico A, Fouts T, Lewis GK, Gallo RC, Godfrey K, Charurat M, et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci U S A (2007) 104:17477-82. doi:10.1073/pnas.0707399104.
59. Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, Flinko R, et al. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci U S A (2013) 110:E69-78. doi:10.1073/pnas.1217609110.
60. Gómez-Román VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, Florese R, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol (2005) 174:2185-9. doi:10.4049/jimmunol.174.4.2185.
61. Moldt B, Schultz N, Dunlop DC, Alpert MD, Harvey JD, Evans DT, et al. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fc? receptors to define the role of effector functions in protection against HIV. J Virol (2011) 85:10572-81. doi:10.1128/JVI.05541-11.
62. Excler JL, Ake J, Robb ML, Kim JH, Plotkin SA. Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines. Clin Vaccine Immunol (2014) 21:1023-36. doi:10.1128/CVI.00230-14.
63. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 369:2083-92. doi:10.1056/NEJMoa1310566.
64. P5 Partnership. Available from: http://www.vaccineenterprise.org/content/P5Partnership (2014).
65. Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis (2012) 12:531-7. doi:10.1016/S1473-3099(12)70088-9.
66. Esparza J. Understanding the efficacy variables of an HIV vaccine trial. Lancet Infect Dis (2012) 12:499-500. doi:10.1016/S1473-3099(12)70117-2.
67. Bregu M, Draper SJ, Hill AV, Greenwood BM. Accelerating vaccine development and deployment: report of a Royal Society satellite meeting. Philos Trans R Soc Lond B Biol Sci (2011) 366:2841-9. doi:10.1098/rstb.2011.0100.
68. Nathanson N, Mathieson BJ. Biological considerations in the development of a human immunodeficiency virus vaccine. J Infect Dis (2000) 182:579-89. doi:10.1086/315707.
69. Medawar PB. Advice to a Young Scientist. New York: Harper Colophon Books (1979).
70. Miedema F. A brief history of HIV vaccine research: stepping back to the drawing board? AIDS (2008) 22:1699-703. doi:10.1097/QAD.0b013e3283021a61.
71. Kaplan D. Point: statistical analysis in NIH peer review-identifying innovation. FASEB J (2007) 21:305-8. doi:10.1096/fj.07-0204ufm.
72. Kaplan D, Lacetera N, Kaplan C. Sample size and precision in NIH peer review. PLoS One (2008) 3:e2761. doi:10.1371/journal.pone.0002761.
73. Parrott C. First grants for innovative AIDS vaccine research awarded. NIAID AIDS Agenda (1997):5-7.
74. Culliton BJ. "Innovation" in AIDS vaccines. Nat Med (1997) 3:1181. doi:10.1038/nm1097-1057a.
75. Varmus H, Klausner R, Zerhouni E, Acharya T, Daar AS, Singer PA. Public health. Grand challenges in global health. Science (2003) 302:398-9. doi:10.1126/science.1091769.
76. McEnery R. The AIDS vaccine field considers ways to encourage innovation and recruit new minds to the effort. IAVI Rep (2009) 13:9-13.
77. Goodwin P. In: Report from the Wellcome-Gates Innovation Meeting. London (2007).
78. Lu W, Chen S, Lai C, Guo W, Fu L, Andrieu JM. Induction of CD8+ regulatory T cells protects macaques against SIV challenge. Cell Rep (2012) 2:1736-46. doi:10.1016/j.celrep.2012.11.016.
79. Andrieu JM, Chen S, Lai C, Guo W, Lu W. Mucosal SIV vaccines comprising inactivated virus particles and bacterial adjuvants induce CD8(+) T-regulatory cells that suppress SIV-positive CD4(+) T-cell activation and prevent SIV infection in the macaque model. Front Immunol (2014) 5:297. doi:10.3389/fimmu.2014.00297.
80. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity (2011) 34:269-80. doi:10.1016/j.immuni.2011.01.015.
81. Leroux-Roels G, Maes C, Clement F, van Engelenburg F, van den Dobbelsteen M, Adler M, et al. Randomized phase I: safety, immunogenicity and mucosal antiviral activity in young healthy women vaccinated with HIV-1 Gp41 P1 peptide on virosomes. PLoS One (2013) 8(2):e55438. doi:10.1371/journal.pone.0055438.
82. McElrath MJ. Standing guard at the mucosa. Immunity (2011) 34:146-8. doi:10.1016/j.immuni.2011.02.014.
83. Zhou M, Ruprecht RM. Are anti-HIV IgAs good guys or bad guys? Retrovirology (2014) 11:109. doi:10.1186/PREACCEPT-1729873135143527.
84. Vieillard V, Strominger JL, Debré P. NK cytotoxicity against CD4+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proc Natl Acad Sci U S A (2005) 102:10981-6. doi:10.1073/pnas.0504315102.
85. Plotkin SA. Problems in vaccine development. Monoclon Antib Immunodiagn Immunother (2014) 33:166-7. doi:10.1089/mab.2014.0011.
86. Sheppard HW, Dorman BP. Time for a systematic look at inactivated HIV vaccines. AIDS (2015) 29:125-7. doi:10.1097/QAD.0000000000000476.
87. Esparza J, Van Regenmortel MH. More surprises in the development of an HIV vaccine. Front Immunol (2014) 5:329. doi:10.3389/fimmu.2014.00329.
88. Van Regenmortel MHV, Andrieu J-M, Dimitrov DS, Ensoli B, Hioe CE, Moog C, et al. Paradigm changes and the future of HIV vaccines: a summary of a workshop held in Baltimore on 20 November 2013. J AIDS Clin Res (2014) 5:281. doi:10.4172/2155-6113.1000281.